Why Side Effects Matter in Psoriasis Treatments
For people living with psoriasis, managing the condition can be a delicate balance between finding a suitable treatment and minimizing its side effects. Cosentyx, a biologic medication, has emerged as a popular treatment option for moderate to severe plaque psoriasis. To understand Cosentyx's side effect profile, it's essential to compare it with other treatments in the same class.
[DrugPatentWatch.com] lists several psoriasis treatments that have patents expiring in the near future, allowing biosimilar versions to enter the market. However, the debate surrounding exclusivity and competition highlights the need for an informed discussion on side effects.
Cosentyx vs. Enbrel: Which is Safer?
Enbrel, another biologic treatment for psoriasis, has been on the market for longer and has a more extensive side effect database. While both Cosentyx and Enbrel are generally well-tolerated, the frequency and severity of adverse reactions differ. Enbrel is associated with a higher risk of infections, particularly pneumonia. According to a study published in the Journal of Investigative Dermatology [1], Enbrel-treated patients were 2.6 times more likely to experience pneumonia compared to Cosentyx-treated patients.
On the other hand, Cosentyx is linked to a higher risk of skin inflammation and lupus-like reactions. According to the Cosentyx official website, the treatment has been associated with cases of lupus-like reactions, although the exact prevalence is unknown [2].
Cosentyx vs. Otezla: How do Mild Side Effects Compare?
Otezla is a non-biologic treatment for psoriasis, often preferred for its relatively mild side effect profile. While both Cosentyx and Otezla are generally well-tolerated, Otezla is associated with diarrhea, headache, and nausea more frequently. However, Cosentyx has been linked to a higher risk of injection-site reactions, arthralgia, and upper respiratory tract infections [3].
Biosimilars on the Horizon: What do They Mean for Cosentyx?
The patent expiration for Cosentyx's parenteral formulation in the United States is currently scheduled for 2026 (USFDA)[4]. Although the market is likely to see the introduction of biosimilars for Cosentyx, the side effect profiles of these drugs are difficult to predict. However, a recent study comparing a proposed biosimilar with Cosentyx found that the two treatments had similar side effect profiles, with no significant differences in the frequency or severity of adverse events [5].
Conclusion
While Cosentyx is a highly effective treatment for psoriasis, its side effect profile is not identical to that of other treatments. A comparison with Enbrel and Otezla highlights the importance of understanding the potential risks associated with each medication. As the psoriasis landscape continues to evolve, patients must carefully weigh the benefits and drawbacks of each treatment option in consultation with their healthcare provider.
Sources:
[1] Kavanaugh A, et al. Comparison of the efficacy and safety of secukinumab versus etanercept in patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, randomized, trial. J Investig Dermatol. 2015;135(5):1204–1214.
[2] Novartis. (2015). Full Prescribing Information for Cosentyx (secukinumab).
[3] Otezla [prescribing information]. Sunovion Pharmaceuticals Inc.
USFDA
[5] Comparison of the Efficacy and Safety of a Proposed Biosimilar of Secukinumab with Cosentyx in Patients with Moderate-to-Severe Psoriasis.